Efficacy of once-weekly teriparatide in patients with glucocorticoid-induced osteoporosis: the TOWER-GO study.

Tanaka I, Tanaka Y, Soen S, Oshima H

Journal of bone and mineral metabolism19 Nov 2020Cited by 8 (Europe PMC)

PMID33211212DOI10.1007/s00774-020-01171-5PepBankPUB-33211212

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In glucocorticoid-induced osteoporosis, teriparatide non-inferiority to alendronate for lumbar spine BMD change was not confirmed.
In plain wordsIn glucocorticoid-induced osteoporosis, the study did not confirm teriparatide non-inferiority to alendronate for spine bone density change.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableLumbar spine BMD non-inferiority
Study
n = 180
Comparator
alendronate 35 mg once weekly
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
56.5 µg once weekly · 72 weeksAs given in this study (human).
Source sentences
Summary
While the non-inferiority of teriparatide to alendronate was not confirmed, BMD increased significantly from baseline with teriparatide and alendronate by 5.09% and 4.04%, respectively (both p < 0.05), at 72 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
The TOWER-GO study, a 72-week, multicenter, open-label, randomized controlled trial, was conducted in patients with GIOP to compare the effects of once-weekly teriparatide and once-weekly alendronate 35 mg on BMD.
Summary · context
Patients (N = 180) with GIOP for whom drug treatment was indicated according to the 2004 guidelines in Japan were randomized to receive once-weekly teriparatide (n = 89) or once-weekly alendronate (n = 91).
Report a problemFND-3321121201
02HumanRandomized controlled trialEfficacy outcome
In glucocorticoid-induced osteoporosis, vertebral fracture incidence was similar with teriparatide and alendronate.
In plain wordsIn glucocorticoid-induced osteoporosis, vertebral fractures occurred similarly with teriparatide and alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeVertebral fracture incidence
Study
n = 180
Comparator
alendronate
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
56.5 µg once weekly · 72 weeksAs given in this study (human).
Source sentences
Summary
The incidence of vertebral and non-vertebral fractures was similar in both groups.
2 context sentences(design, population, supporting numbers)
Summary · context
The TOWER-GO study, a 72-week, multicenter, open-label, randomized controlled trial, was conducted in patients with GIOP to compare the effects of once-weekly teriparatide and once-weekly alendronate 35 mg on BMD.
Summary · context
Patients (N = 180) with GIOP for whom drug treatment was indicated according to the 2004 guidelines in Japan were randomized to receive once-weekly teriparatide (n = 89) or once-weekly alendronate (n = 91).
Report a problemFND-3321121203
03HumanRandomized controlled trialEfficacy outcome
In glucocorticoid-induced osteoporosis, non-vertebral fracture incidence was similar with teriparatide and alendronate.
In plain wordsIn glucocorticoid-induced osteoporosis, non-vertebral fractures occurred similarly with teriparatide and alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeNon-vertebral fracture incidence
Study
n = 180
Comparator
alendronate
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
56.5 µg once weekly · 72 weeksAs given in this study (human).
Source sentences
Summary
The incidence of vertebral and non-vertebral fractures was similar in both groups.
2 context sentences(design, population, supporting numbers)
Summary · context
The TOWER-GO study, a 72-week, multicenter, open-label, randomized controlled trial, was conducted in patients with GIOP to compare the effects of once-weekly teriparatide and once-weekly alendronate 35 mg on BMD.
Summary · context
Patients (N = 180) with GIOP for whom drug treatment was indicated according to the 2004 guidelines in Japan were randomized to receive once-weekly teriparatide (n = 89) or once-weekly alendronate (n = 91).
Report a problemFND-3321121204
04HumanRandomized controlled trialActivity measurement
In glucocorticoid-induced osteoporosis, bone formation markers increased with teriparatide, whereas they decreased with alendronate.
In plain wordsIn glucocorticoid-induced osteoporosis, bone formation markers increased with teriparatide and decreased with alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseBone formation markers
Study
n = 180
Comparator
baseline
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
56.5 µg once weekly · 72 weeksAs given in this study (human).
Source sentences
Summary
Bone formation markers increased in the teriparatide group and decreased in the alendronate group.
2 context sentences(design, population, supporting numbers)
Summary · context
The TOWER-GO study, a 72-week, multicenter, open-label, randomized controlled trial, was conducted in patients with GIOP to compare the effects of once-weekly teriparatide and once-weekly alendronate 35 mg on BMD.
Summary · context
Patients (N = 180) with GIOP for whom drug treatment was indicated according to the 2004 guidelines in Japan were randomized to receive once-weekly teriparatide (n = 89) or once-weekly alendronate (n = 91).
Report a problemFND-3321121205

Studies that did not test the peptide alone1

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

05HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In glucocorticoid-induced osteoporosis, BMD increased from baseline with both teriparatide and alendronate at 72 weeks.
In plain wordsIn glucocorticoid-induced osteoporosis, bone density increased from baseline with both teriparatide and alendronate at 72 weeks.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseBMD change from baseline
Study
n = 180
Comparator
baseline
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Measurements
BMD increase
5.09%
teriparatide
BMD increase
4.04%
alendronate
Source sentences
Summary
While the non-inferiority of teriparatide to alendronate was not confirmed, BMD increased significantly from baseline with teriparatide and alendronate by 5.09% and 4.04%, respectively (both p < 0.05), at 72 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
The TOWER-GO study, a 72-week, multicenter, open-label, randomized controlled trial, was conducted in patients with GIOP to compare the effects of once-weekly teriparatide and once-weekly alendronate 35 mg on BMD.
Summary · context
Patients (N = 180) with GIOP for whom drug treatment was indicated according to the 2004 guidelines in Japan were randomized to receive once-weekly teriparatide (n = 89) or once-weekly alendronate (n = 91).
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3321121202

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.